10.3389/fimmu.2019.02816.s001
Annekathrin Heinze
Annekathrin
Heinze
Beatrice Grebe
Beatrice
Grebe
Melanie Bremm
Melanie
Bremm
Sabine Huenecke
Sabine
Huenecke
Tasleem Ah. Munir
Tasleem Ah.
Munir
Lea Graafen
Lea
Graafen
Jochen T. Frueh
Jochen T.
Frueh
Michael Merker
Michael
Merker
Eva Rettinger
Eva
Rettinger
Jan Soerensen
Jan
Soerensen
Thomas Klingebiel
Thomas
Klingebiel
Peter Bader
Peter
Bader
Evelyn Ullrich
Evelyn
Ullrich
Claudia Cappel
Claudia
Cappel
Image_1_The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their ex vivo Expansion and Cytotoxic Potential Against Neuroblastoma: Perspective for Optimized Immunotherapy Post Haploidentical Stem Cell Transplantation.JPEG
Frontiers
2019
immunotherapy
NK cells
CD3/CD19 depletion
CIK cells
IL-21
IL-15
ex vivo expansion
neuroblastoma
2019-12-03 04:44:49
Figure
https://frontiersin.figshare.com/articles/figure/Image_1_The_Synergistic_Use_of_IL-15_and_IL-21_for_the_Generation_of_NK_Cells_From_CD3_CD19-Depleted_Grafts_Improves_Their_ex_vivo_Expansion_and_Cytotoxic_Potential_Against_Neuroblastoma_Perspective_for_Optimized_Immunotherapy_Post_Haploide/11308985
<p>Neuroblastoma (NB) is the most common solid extracranial tumor in childhood. Despite therapeutic progress, prognosis in high-risk NB is poor and innovative therapies are urgently needed. Therefore, we addressed the potential cytotoxic capacity of interleukin (IL)-activated natural killer (NK) cells compared to cytokine-induced killer (CIK) cells for the treatment of NB. NK cells were isolated from peripheral blood mononuclear cells (PBMCs) by indirect CD56-enrichment or CD3/CD19-depletion and expanded with different cytokine combinations, such as IL-2, IL-15, and/or IL-21 under feeder-cell free conditions. CIK cells were generated from PBMCs by ex vivo stimulation with interferon-γ, IL-2, OKT-3, and IL-15. Comparative analysis of expansion rate, purity, phenotype and cytotoxicity was performed. CD56-enriched NK cells showed a median expansion rate of 4.3-fold with up to 99% NK cell content. The cell product after CD3/CD19-depletion consisted of a median 43.5% NK cells that expanded significantly faster reaching also 99% of NK cell purity. After 10–12 days of expansion, both NK cell preparations showed a significantly higher median cytotoxic capacity against NB cells relative to CIK cells. Remarkably, these NK cells were also capable of efficiently killing NB spheroidal 3D culture in long-term cytotoxicity assays. Further optimization using a novel NK cell culture medium and a prolonged culturing procedure after CD3/CD19-depletion for up to 15 days enhanced the expansion rate up to 24.4-fold by maintaining the cytotoxic potential. Addition of an IL-21 boost prior to harvesting significantly increased the cytotoxicity. The final cell product consisted for the major part of CD16<sup>−</sup>, NCR-expressing, poly-functional NK cells with regard to cytokine production, CD107a degranulation and antitumor capacity. In summary, our study revealed that NK cells have a significantly higher cytotoxic potential to combat NB than CIK cell products, especially following the synergistic use of IL-15 and IL-21 for NK cell activation. Therefore, the use of IL-15+IL-21 expanded NK cells generated from CD3/CD19-depleted apheresis products seems to be highly promising as an immunotherapy in combination with haploidentical stem cell transplantation (SCT) for high-risk NB patients.</p>